The study represents a pioneering approach to gene therapy for Kabuki Syndrome (KS), a rare genetic disorder. By leveraging CRISPR/Cas9 technology for epigenome editing, the research aims to restore the function of the KMT2D gene, which is critical for normal development. The successful establishment of a patient-derived mesenchymal stem cell bio-bank could facilitate further research and potential therapeutic developments. Given the lack of existing treatments for KS, this asset may attract significant interest from biopharmaceutical companies focused on rare diseases and gene therapies. The competitive landscape includes other gene editing technologies and therapies targeting genetic disorders, necessitating a thorough diligence process to assess market entry and partnership opportunities.